Floatz logo

FLUDEOXYGLUCOSE

Type 2 Diabetes

Université de SherbrookeSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

55 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Liraglutide
RenJi Hospital
Phase 4BBB
Pioglitazone
Seoul National University Bundang Hospital
Phase 4BBB
Empagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Sitagliptin
Brigham and Women's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

FLUDEOXYGLUCOSE is also rated in:

Recurrent Adult Brain TumorDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →